Krka DD (FRA:KN8) Other Financing: €-262 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KN8 Krka DD FRA:KN8
66 GF Score
Price €269.00
GF Value €148.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krka DD Other Financing?

Krka DD FRA:KN8 +3.07% 66 Other Financing is €-262 Mil as of Mar. 2026. GuruFocus rates FRA:KN8 with a GF Score™ of 66/100 and a GF Value™ of €148.66 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Krka DD's Other Financing for the three months ended in Mar. 2026 was €-1 Mil.

Krka DD's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-262 Mil.

Krka DD Other Financing Historical Data

* Premium members only.

The historical data trend for Krka DD's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krka DD Other Financing Chart

Krka DD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.83 1.97 -7.34 -4.47 -9.72

Krka DD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.83 -2.40 -255.06 -3.39 -1.26
FRA:KN8
66GF Score
Krka DD FRA:KN8
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krka DD Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-262 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-262 Mil mean?
Krka DD (FRA:KN8) has a Other Financing of €-262 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Krka DD and its competitors.
Is Krka DD's Other Financing too high?
Krka DD's current Other Financing is €-262 Mil. Overall, Krka DD has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Other Financing compare to ZTS and UTHR?
Krka DD's Other Financing of €-262 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Krka DD and its competitors. Krka DD's current Other Financing is €-262 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Significantly Overvalued. The stock's GF Value™ is €148.66, compared to a current price of €269.00 — trading 80.9% above its estimated fair value. The current Other Financing is €-262 Mil. Krka DD's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current Other Financing is €-262 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krka DD (FRA:KN8) Overvalued in 2026?

Based on GuruFocus' analysis, Krka DD stock appears to be overvalued. The current stock price of €269.00 is trading 80.9% above its estimated GF Value™ of €148.66. GuruFocus considers Krka DD to be Significantly Overvalued.

Key valuation signals for FRA:KN8:

  • Other Financing: €-262 Mil
  • GF Value™: €148.66 vs. price of €269.00 (80.9% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krka DD Business Description

Address Smarjeska Cesta 6, Novo Mesto, SVN, 8501
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
66GF Score

Get the complete analysis for FRA:KN8

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€269.00
Price
€148.66
GF Value